This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
04/01/15 - 1:44:59 PM ET (BATS BZX Real-time Price)
Div Yield: --
CVM Day's Range
CVM 52 Week Range
CVM Business Summary
CEL-SCI Corporation engages in the research and development of drugs and vaccines. The company's lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer.View CVM key stats
CEL-SCI Corp - CVM - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates CEL-SCI Corp as a
Sell with a ratings score of D-.
Report Snippet: We rate CEL-SCI Corp (CVM) a Sell.
This is based on the convergence of positive investment measures, which should help this stock outperform the majority
of stocks that we rate. The company's strengths can be seen in multiple areas, such as its solid stock price performance,
growth in earnings per share, revenue growth, notable return on equity and expanding profit margins. Although the company
may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.